Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
CalRx progress on naloxone; insulin timeline remains uncertain amid vendor scrutiny
Summary
HCAI reported progress on a state‑backed naloxone supply contract and ongoing product development with Civica for an affordable insulin glargine product; lawmakers pressed agencies on timelines, confidentiality and a recent opioid‑related settlement involving the selected naloxone manufacturer.
The Department of Health Care Access and Information updated the Assembly subcommittee on CalRx programs to expand access to lower‑cost naloxone and a state‑supported biosimilar insulin glargine product.
Vishal Pagani of HCAI summarized the program history and recent steps. HCAI announced a $50 million CalRx/Civica arrangement in March 2023 to support development of an affordable biosimilar insulin glargine. Pagani said Civica has progressed through initial facility inspections, has manufactured vials and pens at a U.S. facility for upcoming clinical work, and is coordinating supply‑chain plans for distribution after FDA approval. HCAI said it expects Civica to begin clinical trials soon but did not provide a definitive public timeline for insulin availability.
On naloxone, HCAI described a separate, more advanced track. The Legislature provided $25 million in opioid settlement funds for a CalRx naloxone access…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
